Home › Funds › Enavate Sciences GP, LLC › BBOT

Enavate Sciences GP, LLC position in BBOT

BridgeBio Oncology Therapeutic Inc · Health Care

Enavate Sciences GP, LLC reported holding 2,626,946 shares of BBOT (BridgeBio Oncology Therapeutic Inc) in its Q2 2026 13F filing — a position valued at US$20.0M, representing 5.80% of its reported portfolio and ranking #4 among its reported holdings. Enavate Sciences GP, LLC has disclosed BBOT holdings in 4 of the last 4 reported quarters, going back to Q3 2025.

Latest position (Q2 2026)2.63M sh
Reported value held$20.02M
Portfolio Weight5.80%
First reportedQ3 2025
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Enavate Sciences GP, LLC's BBOT position evolved

Enavate Sciences GP, LLC first disclosed a stake in BBOT in Q3 2025 at 2,626,946 shares (US$30.4M). The position peaked in Q4 2025 at 2,626,946 shares, worth US$32.9M. Across 4 filings, Enavate Sciences GP, LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 2,626,946 shares valued at US$20.0M.

Quarter by quarter

QuarterSharesValueChange
Q3 2025 2.63M $30.42M New
Q4 2025 2.63M $32.89M Hold
Q1 2026 2.63M $23.51M Hold
Q2 2026 2.63M $20.02M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BBOT and 13F data

BBOT (BridgeBio Oncology Therapeutic Inc) is a Health Care company. 74 other funds we track also report a position in BBOT — the largest reported positions include Cormorant Asset Management, LP (US$136.2M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$37.2M), Omega Fund Management, LLC (US$25.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BBOT

All BBOT fund holders →

FAQ

How long has Enavate Sciences GP, LLC held BBOT?

Enavate Sciences GP, LLC has disclosed BBOT holdings in 4 of the last 4 reported quarters, going back to Q3 2025.

What is Enavate Sciences GP, LLC's current position in BBOT?

As of Q2 2026, Enavate Sciences GP, LLC holds 2.63M shares of BBOT (BridgeBio Oncology Therapeutic Inc), valued at $20.02M, representing 5.80% of its reported portfolio and ranking #4.

Has Enavate Sciences GP, LLC been buying or selling BBOT?

In the latest 13F filing (Q2 2026), Enavate Sciences GP, LLC held unchanged its position in BBOT. The position peaked in Q4 2025 at 2.63M shares.

Which other funds hold BBOT?

Other major institutional holders of BBOT include Cormorant Asset Management, LP, DEERFIELD MANAGEMENT COMPANY, L.P., Omega Fund Management, LLC, among 74 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.